We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.50 | 0.98% | 1,599.00 | 1,599.50 | 1,600.50 | 1,600.00 | 1,575.00 | 1,579.50 | 5,149,016 | 16:35:14 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.37 | 65.87B |
From Apr 2019 to Apr 2024
By Ian Walker
LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it would sell its rights in ofatumumab for auto-immune indications, including multiple sclerosis, to Novartis AG (NVS) for up to $1 billion, plus royalties.
The deal follows a previously agreed asset swap between the two companies, which was completed earlier this year.
Upon completion of the latest transaction, which is expected by the end of the year, Novartis will own rights to ofatumumab in all indications. Under the deal, Novartis will also pay royalties of up to 12% to Glaxo on any future net sales of ofatumumab in auto-immune indications.
"We continue to focus on progressing our pipeline in core therapy areas including HIV, oncology, vaccines, cardiovascular, immuno-inflammation and respiratory diseases. We believe GSK's pipeline has significant potential to drive long-term performance for the Group and will be profiling it further at our R&D event in November," Glaxo Chief Strategy Office David Redfern said.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 21, 2015 02:04 ET (06:04 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
